# A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

> **NCT00483834** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 50 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00483834
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483834, "A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00483834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*